-
Subject Areas on Research
-
4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial.
-
4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia.
-
5-Fluorouracil, cyclophosphamide, and vincristine for adenoid cystic carcinoma of the head and neck.
-
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.
-
64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.
-
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.
-
A Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer.
-
A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy.
-
A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL.
-
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
-
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.
-
A grafted ovarian fragment rescues host fertility after chemotherapy.
-
A malignant lymphoma with histological features and immunophenotypic profile intermediate between EBV-positive diffuse large B-cell lymphoma and EBV-positive classical Hodgkin lymphoma in a 67-year-old female: a "gray zone" lymphoma associated with Epstein-Barr virus in the elderly.
-
A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma.
-
A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.
-
A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies.
-
A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors.
-
A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. CALGB.
-
A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma.
-
A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET.
-
A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant.
-
A preliminary investigation of the parallelogram concept in genetic monitoring and risk estimation.
-
A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
-
ANZCCSG BabyBrain99; intensified systemic chemotherapy, second look surgery and involved field radiation in young children with central nervous system malignancy.
-
Activation of cyclophosphamide for in vitro testing of cell sensitivity.
-
Activity of high-dose cyclophosphamide in the treatment of childhood malignant gliomas.
-
Activity of intrathecal 4-hydroperoxycyclophosphamide in a nude rat model of human neoplastic meningitis.
-
Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States.
-
Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons.
-
Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma.
-
Adjuvant chemotherapy in older women with early-stage breast cancer.
-
Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. A Southwest Oncology Group study.
-
Adjuvant sequential chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil (ACMF) with concurrent radiotherapy in resectable advanced breast cancer.
-
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
-
Advanced prostatic carcinoma: pulmonary manifestations.
-
Adverse hypersensitivity reactions to mesna as adjunctive therapy for cyclophosphamide.
-
Age and the treatment of multiple myeloma. Southeastern Cancer Study Group experience.
-
Aging and reactivation of latent murine cytomegalovirus.
-
Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome.
-
Allogeneic marrow transplantation for acute leukemia in relapse.
-
Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors.
-
Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors.
-
Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis.
-
Allogeneic marrow transplantation using fractionated total body irradiation in patients with acute lymphoblastic leukemia in relapse.
-
Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease.
-
Amelioration of the cytotoxic effects of chemotherapeutic agents by grape seed proanthocyanidin extract.
-
Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.
-
Amiodarone and cyclophosphamide: potential for enhanced lung toxicity.
-
An in vitro assay procedure to test chemotherapeutic drugs on cells from human solid tumors.
-
An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer.
-
Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience.
-
Anti-Müllerian hormone: a better marker of ovarian damage from cyclophosphamide.
-
Anti-receptor antibody-induced H-Y-specific delayed-type hypersensitivity responses in nonresponder mice.
-
Anticipatory immune suppression and nausea in women receiving cyclic chemotherapy for ovarian cancer.
-
Antirheumatic medications in pregnancy and breastfeeding.
-
Are autoantibodies the targets of B-cell-directed therapy?
-
Arteritis with impaired renal function.
-
Assessment of Early Radiation-Induced Changes in Left Ventricular Function by Myocardial Strain Imaging After Breast Radiation Therapy.
-
Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer.
-
Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer.
-
Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination.
-
Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience.
-
Bilateral episcleritis as a manifestation of cutaneous leukocytoclastic vasculitis.
-
Bone marrow transplantation for thalassemia. The USA experience.
-
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.
-
Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest radiotherapy.
-
Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies.
-
Busulfan therapy of central nervous system xenografts in athymic mice.
-
Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study.
-
Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia.
-
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
-
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
-
CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma.
-
CLL-137 SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine + Rituximab (BR) in Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/ SLL).
-
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
-
Cancer chemotherapeutic response and intravenous hyperalimentaion.
-
Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation.
-
Carboplatin pharmacokinetics in young children with brain tumors.
-
Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
-
Cardiac cell toxicity induced by 4-hydroperoxycyclophosphamide is modulated by glutathione.
-
Cataracts after total body irradiation and marrow transplantation: a sparing effect of dose fractionation.
-
Cellular mechanisms of cyclophosphamide resistance: model studies in human medulloblastoma cell lines.
-
Chemoradiotherapy toxicity during bone marrow transplantation: time course and variation in pain and nausea.
-
Chemotherapy and radiation therapy of human medulloblastoma in athymic nude mice.
-
Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting.
-
Chemotherapy-induced apoptosis in epithelial ovarian cancers.
-
Childhood hepatic mesenchymoma: successful treatment with surgery and multiple-agent chemotherapy.
-
Childhood rhabdomyosarcoma. Analysis of coordinated therapy and results.
-
Chronic CSF leak into the peritoneal cavity shown by radionuclide cisternography. Successful treatment with an epidural blood patch.
-
Chronic brucellosis--clinical response to reduction of suppressor T lymphocytes by cyclophosphamide/prednisone.
-
Chronic lymphocytic leukemia.
-
Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer.
-
Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma.
-
Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood.
-
Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.
-
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
-
Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.
-
Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.
-
Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
-
Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis.
-
Clostridium septicum abscess in hepatic metastases: successful medical management.
-
Cogan's syndrome and development of ANCA-associated renal vasculitis after lengthy disease remission.
-
Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study.
-
Combination chemotherapy and radiation therapy of undifferentiated small cell bronchogenic carcinoma.
-
Combination chemotherapy for osteosarcoma.
-
Combination chemotherapy in histiocytosis X.
-
Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma.
-
Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group.
-
Combination chemotherapy with vincristine, cyclophosphamide, and prednisone producing long-term remission of a transplanted canine lymphoma.
-
Combined medical and surgical therapy for complicated cases of peripheral uveitis.
-
Combined modality therapy for advanced, diffuse lymphocytic and histiocytic lymphomas.
-
Combined modality therapy of advanced non-Hodgkin's lymphoma: an analysis of remission duration and survival in 95 patients.
-
Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy.
-
Comparing Presenting Clinical Features in 48 Children With Microscopic Polyangiitis to 183 Children Who Have Granulomatosis With Polyangiitis (Wegener's): An ARChiVe Cohort Study.
-
Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation.
-
Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.
-
Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).
-
Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine.
-
Comparison of serial PET and MRI scans in a pediatric patient with a brainstem glioma.
-
Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma.
-
Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group.
-
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
-
Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment.
-
Correction of hypoprothrombinemia by immunosuppressive treatment of the lupus anticoagulant-hypoprothrombinemia syndrome.
-
Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
-
Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.
-
Cumulative incidence of secondary solid malignant tumors in aplastic anemia patients given marrow grafts after conditioning with chemotherapy alone.
-
Current therapies for lupus nephritis in an ethnically heterogeneous cohort.
-
Cutaneous polyarteritis nodosa. Report of a case associated with Crohn's disease.
-
Cyclocreatine in cancer chemotherapy.
-
Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia.
-
Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study.
-
Cyclophosphamide for lupus during pregnancy.
-
Cyclophosphamide for the treatment of progressive low-grade astrocytoma: a Pediatric Oncology Group phase II Study.
-
Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma.
-
Cyclophosphamide in scleroderma lung disease.
-
Cyclophosphamide plus ATG conditioning is insufficient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matched unrelated donors.
-
Cyclophosphamide resistance in medulloblastoma.
-
Cyclophosphamide therapy of medulloblastoma: from the laboratory to the clinic and back again (and again and again).
-
Cyclophosphamide therapy of peripheral uveitis.
-
Cyclophosphamide therapy of severe systemic necrotizing vasculitis.
-
Cyclophosphamide treatment of diabetes insipidus in Wegener's granulomatosis.
-
Cyclophosphamide treatment used to manipulate the immune response for the production of monoclonal antibodies.
-
Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy.
-
Cyclophosphamide-asparaginase- vincristine-prednisone induction therapy in childhood acute lymphocytic and nonlymphocytic leukemia.
-
Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.
-
Cyclophosphamide-induced cystitis results in NLRP3-mediated inflammation in the hippocampus and symptoms of depression in rats.
-
Cytogenetic studies and their clinical correlates in adults with acute leukemia.
-
Cytokinetically based induction chemotherapy and splenectomy for childhood acute nonlymphocytic leukemia.
-
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms.
-
Diabetes insipidus associated with Wegener's granulomatosis successfully treated with cyclophosphamide.
-
Different patterns of relapse associated with three intensive treatment regimens for pediatric E-rosette positive T-cell leukemia: a Pediatric Oncology Group study.
-
Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis.
-
Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells.
-
Dissimilar courses of twins with leukemia.
-
Do adult disease severity subclassifications predict use of cyclophosphamide in children with ANCA-associated vasculitis? An analysis of ARChiVe study treatment decisions.
-
Dose escalation trial of cyclophosphamide with Sargramostim in the treatment of central nervous system (CNS) neoplasms.
-
Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma.
-
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
-
Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
-
Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.
-
Dose-finding study of oral idarubicin and cyclophosphamide in first-line treatment of elderly patients with metastatic breast cancer.
-
Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphoma.
-
Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
-
Early and late interstitial pneumonia following human bone marrow transplantation.
-
Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma.
-
Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907.
-
Effect of antineoplastic agents on smooth muscle cell proliferation in vitro: implications for prevention of restenosis after transluminal angioplasty.
-
Effect of chemotherapy on uptake of alkali metals by experimental tumors.
-
Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia.
-
Effect of intravesical nitric oxide therapy on cyclophosphamide-induced cystitis.
-
Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: a randomized, placebo-controlled, double-blind trial.
-
Effects of continuous or discontinuous maintenance therapy on subsequent remission maintenance in childhood leukemia.
-
Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: a Pediatric Oncology Group report.
-
Effects of interleukin-3 on hematopoietic recovery after 5-fluorouracil or cyclophosphamide treatment of cynomolgus primates.
-
Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease.
-
Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma.
-
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
-
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
-
Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma.
-
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
-
Epithelioid Hyalinizing Sarcoma With MGA-NUTM1 Fusion.
-
Etanercept plus standard therapy for Wegener's granulomatosis.
-
Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study.
-
Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer.
-
Evaluating the role of magnetic resonance imaging post-neoadjuvant therapy for breast cancer in the NEONAB trial.
-
Evaluation of pre-radiotherapy cyclophosphamide in patients with newly diagnosed glioblastoma multiforme. Writing Committee for The Brain Tumor Center at Duke.
-
Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamide.
-
Experimental chemotherapy of human medulloblastoma with classical alkylators.
-
Expression and function of transforming growth factor-β isoforms and cognate receptors in the rat urinary bladder following cyclophosphamide-induced cystitis.
-
Extrapolation of Adult Efficacy Data to Pediatric Systemic Lupus Erythematosus: Evaluating Similarities in Exposure-Response.
-
Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anaemia.
-
Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells.
-
Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study.
-
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).
-
Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma.
-
Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies.
-
Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.
-
Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy.
-
Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study.
-
Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission.
-
Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
-
Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
-
Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma.
-
Functional role of thromboxane production by acutely rejecting renal allografts in rats.
-
Gene expression signatures that predict radiation exposure in mice and humans.
-
Generating monoclonal antibodies to neuronal antigens.
-
Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21.
-
Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity.
-
Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment.
-
Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms.
-
Graft-versus-host disease prophylaxis with methotrexate/cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts.
-
Growth and development after bone marrow transplantation.
-
Growth and development following marrow transplantation for leukemia.
-
Haemopoietic stem-cell transplantation for systemic sclerosis.
-
Hair regrowth after cancer therapy.
-
Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial.
-
Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl.
-
Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. VIII. Suppressor cell pathways in cutaneous sensitivity responses.
-
Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541.
-
Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.
-
High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.
-
High dose chemotherapy with autologous peripheral blood progenitor cell transplantation in an anephric child with multiply recurrent Wilms tumor.
-
High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150.
-
High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors.
-
High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma.
-
High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer.
-
High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity.
-
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.
-
High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes.
-
High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas.
-
High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors.
-
High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer.
-
High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.
-
High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study.
-
High-dose cyclophosphamide (NSC-26271) therapy in childhood acute leukemia.
-
High-dose cyclophosphamide and etoposide for patients with refractory acute myeloid leukemia: a case series.
-
High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
-
High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy.
-
High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia.
-
High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
-
High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma.
-
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.
-
High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis.
-
High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes.
-
High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
-
High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study.
-
High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial.
-
High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma.
-
High-risk gestational trophoblastic neoplasia with brain metastases: individualized multidisciplinary therapy in the management of four patients.
-
High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031).
-
Hyperexpansion of Functional Viral-Specific CD8+ T Cells in Lymphopenia-Associated MCMV Pneumonitis.
-
Hypertensive reactions associated with paclitaxel.
-
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
-
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
-
Imaging findings of hemorrhagic cystitis in pediatric oncology patients.
-
Immediate and delayed neurotoxicity after mechlorethamine preparation for bone marrow transplantation.
-
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
-
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
-
Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
-
Immunopharmacologic purging of breast cancer from bone marrow for autologous bone marrow transplantation.
-
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.
-
Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana.
-
Impact of Right Ventricle-Pulmonary Artery Coupling on Clinical Outcomes in the PARTNER 3 Trial.
-
Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study.
-
Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging.
-
Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy.
-
Improving outcomes in advanced DLBCL: systemic approaches and radiotherapy.
-
In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
-
In vitro chemotherapy testing of transitional cell carcinoma.
-
In vivo bioluminescence imaging monitoring of hypoxia-inducible factor 1alpha, a promoter that protects cells, in response to chemotherapy.
-
Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
-
Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.
-
Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.
-
Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials.
-
Individual responses to chemotherapy-induced oxidative stress.
-
Inefficient dystrophin expression after cord blood transplantation in Duchenne muscular dystrophy.
-
Inflammasomes are important mediators of cyclophosphamide-induced bladder inflammation.
-
Inflammatory breast carcinoma. Effective multimodal approach.
-
Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251.
-
Intensive outpatient adjuvant therapy for breast cancer: results of dose escalation and quality of life.
-
Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B.
-
Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis.
-
Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide.
-
Late effects on gonadal function of cyclophosphamide, total-body irradiation, and marrow transplantation.
-
Long-term antimüllerian hormone patterns differ by cancer treatment exposures in young breast cancer survivors.
-
Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer.
-
Long-term follow-Up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia.
-
Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin.
-
Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center.
-
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
-
Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans.
-
Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide.
-
Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial.
-
Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
-
Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302).
-
Lymphoblastic lymphoma in children--a randomized trial comparing LSA2-L2 with the A-COP+ therapeutic regimen: a Pediatric Oncology Group Study.
-
Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy.
-
Lymphomatoid Granulomatosis. Prospective clinical and therapeutic experience over 10 years.
-
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
-
MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.
-
MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer.
-
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.
-
Machine learning predicts stem cell transplant response in severe scleroderma.
-
Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma.
-
Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients.
-
Management of childhood onset nephrotic syndrome.
-
Management of metastatic prostatic cancer.
-
Management of patients with confirmed and presumed mucous membrane pemphigoid undergoing entropion repair.
-
Management of pineal non-germinoma germ cell tumor with residual teratoma and normal alpha-fetoprotein.
-
Managing the complications of plasma cell myeloma.
-
Marrow transplant experience for children with severe aplastic anemia.
-
Marrow transplant experience in children with acute lymphoblastic leukemia: an analysis of factors associated with survival, relapse, and graft-versus-host disease.
-
Marrow transplantation following escalating doses of fractionated total body irradiation and cyclophosphamide--a phase I trial.
-
Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiation.
-
Marrow transplantation for Fanconi anemia with or without leukemic transformation: an update of the Seattle experience.
-
Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation.
-
Marrow transplantation for aplastic anemia.
-
Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide.
-
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.
-
Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia.
-
Marrow transplantation from HLA-identical siblings for treatment of aplastic anemia: is exposure to marrow donor blood products 24 hours before high-dose cyclophosphamide needed for successful engraftment?
-
Marrow transplantation in hepatitis-associated aplastic anemia.
-
Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients.
-
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
-
Mediastinal large cell lymphoma. An uncommon subset of adult lymphoma curable with combined modality therapy.
-
Meningeal mycosis fungoides: clinical and cellular characteristics.
-
Merkel cell carcinoma with partial B-cell blastic immunophenotype: a potential mimic of cutaneous richter transformation in a patient with chronic lymphocytic lymphoma.
-
Metastatic thymoma with myasthenia gravis: complete remission with combination chemotherapy.
-
MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma.
-
MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
-
Modified LSA2-L2 treatment in 53 children with E-rosette-positive T-cell leukemia: results and prognostic factors (a Pediatric Oncology Group Study).
-
Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy.
-
Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase.
-
Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise.
-
Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma.
-
Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies.
-
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
-
Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures.
-
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.
-
Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens.
-
NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.
-
Neurocognitive outcome 12 months following cerebellar mutism syndrome in pediatric patients with medulloblastoma.
-
Neurologic complications after allogeneic marrow transplantation for sickle cell anemia.
-
Never underestimate a dermal lesion: reflections on a rare tumor.
-
New approach to the activation of anti-cancer pro-drugs by metalloporphyrin-based cytochrome P450 mimics in all-aqueous biologically relevant system.
-
Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy.
-
Nonlymphoblastic lymphoma in children--histology and stage-related response to therapy: a Pediatric Oncology Group study.
-
O6-benzylguanine-mediated enhancement of chemotherapy.
-
Ocular toxicity following high dose chemotherapy and autologous transplant.
-
Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial.
-
Orbital granulomatosis with polyangiitis (Wegener granulomatosis): clinical and pathologic findings.
-
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
-
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.
-
Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone.
-
Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation.
-
Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
-
Ovarian function following marrow transplantation for aplastic anemia or leukemia.
-
Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's).
-
Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.
-
PROMACE-MOPP and intrathecal chemotherapy for CNS lymphomas.
-
Paraneoplastic pemphigus associated with non-Hodgkin lymphoma.
-
Pathogenesis of pneumococcal pneumonia in cyclophosphamide-induced leukopenia in mice.
-
Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy.
-
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
-
Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma.
-
Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis.
-
Peripheral T-cell lymphoma with unusual clinical presentation of rhabdomyolysis.
-
Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma.
-
Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group.
-
Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
-
Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907).
-
Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice.
-
Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer.
-
Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma.
-
Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001).
-
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.
-
Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
-
Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer.
-
Phase II study demonstrating failure of both a five-drug continuous-therapy regimen and a two-drug pulse-therapy regimen in the treatment of metastatic neuroblastoma: Southwest Oncology Group Study 822.
-
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.
-
Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma.
-
Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B.
-
Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis.
-
Pilot study of modified LMB-based therapy for children with ataxia-telangiectasia and advanced stage high grade mature B-cell malignancies.
-
Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001).
-
Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B.
-
Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models.
-
Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation.
-
Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort.
-
Preradiation chemotherapy in advanced medulloblastoma. A Pediatric Oncology Group pilot study.
-
Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
-
Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.
-
Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.
-
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
-
Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up.
-
Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
-
Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients.
-
Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45).
-
Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B.
-
Purification and partial characterization of a human hematopoietic precursor population.
-
Purinergic signalling underlies transforming growth factor-β-mediated bladder afferent nerve hyperexcitability.
-
Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
-
Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907.
-
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.
-
Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905.
-
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
-
Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.
-
Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study.
-
Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer.
-
Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma.
-
Rational approaches to the chemotherapy of medulloblastoma.
-
Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
-
Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691.
-
Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease.
-
Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901.
-
Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
-
Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy.
-
Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
-
Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation in the scleroderma: cyclophosphamide or transplantation trial.
-
Repair analysis of 4-hydroperoxycyclophosphamide-induced DNA interstrand crosslinking in the c-myc gene in 4-hydroperoxycyclophosphamide-sensitive and -resistant medulloblastoma cell lines.
-
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study).
-
Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer.
-
Rhabdomyosarcoma in adult prostate.
-
Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.
-
Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer.
-
Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
-
Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome.
-
Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy.
-
Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.
-
Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.
-
Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
-
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
-
Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group.
-
Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation.
-
Role of glutathione in cellular resistance to alkylating agents.
-
Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial.
-
Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
-
Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma.
-
Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.
-
Second marrow transplants in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin.
-
Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant.
-
Selection of patients with Hodgkin's disease and non-Hodgkin's lymphoma for bone marrow transplantation.
-
Sensory pudendal nerve stimulation increases bladder capacity through sympathetic mechanisms in cyclophosphamide-induced cystitis rats.
-
Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors.
-
Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.
-
Simvastatin suppresses cyclophosphamide-induced changes in urodynamics and bladder inflammation.
-
Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program.
-
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.
-
Small lymphocytic lymphoma presenting as a paraneoplastic syndrome with acute central nervous system demyelination.
-
Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program.
-
Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts.
-
Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.
-
Stromal gene signatures in large-B-cell lymphomas.
-
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.
-
Study on the comparability of 6 versus 12 cycles of adjuvant cyclophosphamide, methotrexate, and fluorouracil.
-
Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine.
-
Successful treatment of childhood pilocytic astrocytomas metastatic to the leptomeninges with high-dose cyclophosphamide.
-
Successful treatment of pediatric histiocytic sarcoma using abbreviated high-risk leukemia chemotherapy.
-
Surrogate tolerogenesis: possible pretransplant induction of accommodation of pig xenografts.
-
Susac syndrome with transient inverted vision.
-
Swainsonine protects both murine and human haematopoietic systems from chemotherapeutic toxicity.
-
Synergistic cytotoxicity using 2'-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells.
-
Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft.
-
Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation.
-
TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).
-
Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response.
-
Targeting Tumor Acidosis and Regulatory T Cells Unmasks Anti-Metastatic Potential of Local Tumor Ablation in Triple-Negative Breast Cancer.
-
Ten years' experience with LSA2-L2 therapy for childhood advanced lymphoblastic lymphoma.
-
The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
-
The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study.
-
The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data.
-
The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients.
-
The effects of cytotoxic therapy in progressive IgA nephropathy.
-
The effects of tempol on cyclophosphamide-induced oxidative stress in rat micturition reflexes.
-
The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.
-
The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide.
-
The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy.
-
The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease.
-
The pediatric preclinical testing program: description of models and early testing results.
-
The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction.
-
The prognostic value of interim and end-of-treatment PET/CT in patients with newly diagnosed peripheral T-cell lymphoma.
-
The radiographic diagnosis and treatment of paraneoplastic central nervous system disease.
-
The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
-
The role of optimal debulking in advanced stage serous carcinoma of the uterus.
-
The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations.
-
The use of lithium carbonate to reduce infection and leukopenia during systemic chemotherapy.
-
Therapeutic approaches to the treatment of rheumatoid disease.
-
Therapeutic vaccines for aggressive B-cell lymphoma.
-
Therapy for granulomatous angiitis.
-
Therapy of myeloma.
-
Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma.
-
Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study.
-
Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey.
-
Treatment modalities in Guillain-Barré syndrome.
-
Treatment of high-stage bladder cancer: case for adjunctive chemotherapy.
-
Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation.
-
Treatment of patients with pineoblastoma with high dose cyclophosphamide.
-
Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine.
-
Treatment of recurrent and metastatic cervical cancer with cis-platin, doxorubicin, and cyclophosphamide.
-
Treatment of red cell aplasia with antithymocyte globulin: repeated inductions of complete remissions in two patients.
-
Treatment of trilateral retinoblastoma with vincristine and cyclophosphamide.
-
Treatment of vasculitis with cyclophosphamide.
-
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.
-
Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes.
-
Undertreatment of obese women receiving breast cancer chemotherapy.
-
Urinary biomarkers of oxidative status in a clinical model of oxidative assault.
-
Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-onset Systemic Lupus Erythematosus in North America.
-
Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma.
-
Vasculitis and Pregnancy.
-
Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years.
-
What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?
-
What started this? Debilitating longitudinally-extensive myelitis.
-
Keywords of People
-
-
Allen, Nancy Bates,
Professor Emeritus of Medicine,
Medicine, Rheumatology and Immunology
-
Berchuck, Andrew,
James M. Ingram Distinguished Professor of Gynecologic Oncology,
Obstetrics and Gynecology, Gynecologic Oncology
-
Craciunescu, Oana,
Professor of Radiation Oncology,
Radiation Oncology
-
McLendon, Roger Edwin,
Professor of Pathology,
Pathology